Format

Send to

Choose Destination
Drug Discov Today. 2015 Jan;20(1):122-8. doi: 10.1016/j.drudis.2014.10.003. Epub 2014 Oct 17.

Peptide therapeutics: current status and future directions.

Author information

1
Zealand Pharma A/S, Smedeland 36, Glostrup, 2600 Copenhagen, Denmark.
2
Zealand Pharma A/S, Smedeland 36, Glostrup, 2600 Copenhagen, Denmark. Electronic address: tho@zealandpharma.com.

Abstract

Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates. Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.

PMID:
25450771
DOI:
10.1016/j.drudis.2014.10.003
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center